← All trials
NCT02160899
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2014
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 65
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Ionis Pharmaceuticals, Inc.Lead sponsor
- University of AmsterdamOverall official - principal investigator
- University of CopenhagenOverall official - principal investigator
- Sint Franciscus GasthuisOverall official - principal investigator
- Utrecht UniversityOverall official - principal investigator
- Clinique des Maladies Lipidiques de Quebec Inc.Overall official - principal investigator
- Barlow Medical CentreOverall official - principal investigator
- Uniklinik Koeln, Zentrum fuer Endokrinologie, Diabetologie und PraeventivmedizinOverall official - principal investigator
- Maastricht UniversityOverall official - principal investigator
- University of BirminghamOverall official - principal investigator
- Radboud UniversityOverall official - principal investigator
- Chicoutimi HospitalOverall official - principal investigator
- Otto von Guericke UniversityOverall official - principal investigator
- University of MunsterOverall official - principal investigator
- Humboldt UniversityOverall official - principal investigator
- Newcastle UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.